Tseng Horng-Ta, Lin Yi-Wen, Sung Shih-Ying, Tsai Yi-Ting, Liu Chen-Wei, Hsu Po-Shun, Tsai Chien-Sung, Lin Feng-Yen
Taipei Heart Institute, Taipei Medical University, Taipei, 11031, Taiwan.
Division of Cardiology and Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, 11031, Taiwan.
Tissue Eng Regen Med. 2025 Apr;22(3):273-284. doi: 10.1007/s13770-025-00710-3. Epub 2025 Mar 3.
Atherosclerosis often leads to ischemic heart disease and peripheral artery disease. Traditional revascularization technique such as bypass grafting using autologous vessels are commonly employed. However, limitations arise when patients lack suitable grafts due to underlying diseases or previous surgeries, prompting the need to substitute vessel grafts. Due to the high biocompatibility of decellularized products (grafts or scaffolds) prepared using supercritical carbon dioxide (ScCO), it has been widely applied in decellularization-related technologies in recent years. Therefore, this review article will comprehensively discuss the current developments in tissue vascular scaffolds applied to the treatment of cardiovascular diseases, with a particular focus on the application of supercritical carbon dioxide technology in this field and the challenges it faces.
This review was compiled by searching relevant references on PubMed database (before June 2024) based on selected key words and specific terms.
ScCO is an effective and eco-friendly extraction agent widely used in industries like food, pharmaceuticals, and cosmetics. It has been applied in decellularization processes to obtain extracellular matrices (ECMs) from tissues. ScCO technology has emerged as a promising method in cardiovascular disease treatment, particularly for developing tissue vascular scaffolds. ScCO effectively removes cellular components while preserving the ECM, ensuring high biocompatibility and reduced immune response. It has been applied to decellularize tissues like heart valves and arteries, creating scaffolds that mimic natural ECM to support cell proliferation and tissue regeneration. Despite challenges such as solubility limitations and cost, ScCO offers advantages like low toxicity and ease of use, making it a valuable tool in advancing regenerative medicine for cardiovascular applications.
ScCO has the advantages of low cellular toxicity, cost-effectiveness, and ease of manipulation. These characteristics have the potential to lead to significant progress in cardiovascular research on tissue regeneration.
动脉粥样硬化常导致缺血性心脏病和外周动脉疾病。传统的血管重建技术,如使用自体血管进行搭桥手术,是常用的方法。然而,当患者由于基础疾病或既往手术而缺乏合适的移植物时,就会出现局限性,这促使人们需要替代血管移植物。由于使用超临界二氧化碳(ScCO)制备的脱细胞产品(移植物或支架)具有高度的生物相容性,近年来它已广泛应用于脱细胞相关技术。因此,这篇综述文章将全面讨论应用于心血管疾病治疗的组织血管支架的当前发展情况,特别关注超临界二氧化碳技术在该领域的应用及其面临的挑战。
本综述通过在PubMed数据库(截至2024年6月)中基于选定的关键词和特定术语搜索相关参考文献进行编撰。
ScCO是一种有效且环保的萃取剂,广泛应用于食品、制药和化妆品等行业。它已被应用于脱细胞过程,以从组织中获得细胞外基质(ECM)。ScCO技术已成为心血管疾病治疗中一种有前景的方法,特别是在开发组织血管支架方面。ScCO能有效去除细胞成分,同时保留ECM,确保高生物相容性并减少免疫反应。它已被应用于对心脏瓣膜和动脉等组织进行脱细胞处理,制造出模仿天然ECM以支持细胞增殖和组织再生的支架。尽管存在溶解度限制和成本等挑战,但ScCO具有低毒性和易用性等优点,使其成为推进心血管应用再生医学的宝贵工具。
ScCO具有细胞毒性低、成本效益高和易于操作的优点。这些特性有可能在心血管组织再生研究方面取得重大进展。